Patent · US Active

Anti-OX40 antibodies and methods of activating OX40

US11242398B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

REMD Biotherapeutics, Inc. · US

Inventors

Frank J. Calzone · Westlake Village, US
Hai Yan · Chapel Hill, US
John Zhang · New York, US

Key dates

Filing date	Aug 1, 2018
Grant date	Feb 8, 2022
Priority date	—
Expiry date	Jan 9, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting OX40 expressed on injured tissues associated with multiple diseases. These OX40 antibodies, or antigen-binding fragments thereof, have a high affinity for OX40 and function as OX40 agonists or as OX40/OX40L antagonists. The antibodies and antigen-binding fragments are useful for treatment of human diseases, infections, and other conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.